Abstract
Human Respiratory Syncytial Virus (hRSV) is one of the main causes of acute respiratory diseases such as bronchiolitis and pneumonia in newborns, children, and elderly. To date, there is no effective vaccine against hRSV, and the only licensed treatment commonly offered, a monoclonal antibody targeting the viral fusion protein, is a high-cost drug that has presented adverse reactions. The…